نتایج جستجو برای: ranolazine

تعداد نتایج: 610  

2014
Samuel Sossalla Nora Wallisch Karl Toischer Christian Sohns Dirk Vollmann Joachim Seegers Lars Lüthje Lars S Maier Markus Zabel

PURPOSE Torsades de pointes (TdP) tachycardias are triggered, polymorphic ventricular arrhythmias arising from early afterdepolarizations (EADs) and increased dispersion of repolarization. Ranolazine is a new agent which reduces pathologically elevated late INa but also IKr . Aim of this study was to evaluate the effects of ranolazine in a validated isolated Langendorff-perfused rabbit heart mo...

Journal: :Journal of atrial fibrillation 2014
Dionyssios Leftheriotis Panayota Flevari George Theodorakis Angelos Rigopoulos Ignatios Ikonomidis Fotis Panou Vassilios Sourides Panagiotis Simitsis Georgios Giannakakis Isaac Aidonidis Ioannis Rizos Maria Anastasiou-Nana

The impact of ranolazine, an anti-ishemic agent with antiarrhythmic properties, on paroxysmal atrial fibrillation (PAF) in patients with coronary artery disease (CAD) remains unclear. Pacing devices can be useful tools for disclosing even asymptomatic PAF. Purpose of this study is to assess the effect of ranolazine on atrial fibrillation (AF), in patients with CAD, PAF and a dual-chamber pacema...

2015
Anvesha Singh Jamal N Khan Christopher D Steadman Michael Jerosch-Herold Sheraz A Nazir Prathap Kanagala Gerry P McCann

Background Aortic Stenosis (AS) is characterized by pressure overload hypertrophy (LVH) with associated diastolic dysfunction. The presence of LVH, diastolic dysfunction and microvascular dysfunction appear to be important determinants of exercise capacity in AS. There are no medical therapies in AS of proven value. Ranolazine is licenced for the treatment of angina and inhibits late sodium cha...

2010
Mark Estacion Stephen G Waxman Sulayman D Dib-Hajj

BACKGROUND A direct role of sodium channels in pain has recently been confirmed by establishing a monogenic link between SCN9A, the gene which encodes sodium channel Nav1.7, and pain disorders in humans, with gain-of-function mutations causing severe pain syndromes, and loss-of-function mutations causing congenital indifference to pain. Expression of sodium channel Nav1.8 in DRG neurons has als...

Journal: :European Heart Journal 2022

Abstract Background Although ranolazine is available since years as a second-line treatment to reduce angina attacks in patients with stable pectoris, real-world data on effectiveness, tolerability and safety of are limited. Methods A non-interventional, prospective study conducted assess the effectiveness ranolazine. Patients eligible for enrolment had baseline assessment between one fourteen ...

Journal: :American journal of physiology. Heart and circulatory physiology 2011
Andrew C Zygmunt Vladislav V Nesterenko Sridharan Rajamani Dan Hu Hector Barajas-Martinez Luiz Belardinelli Charles Antzelevitch

Atrial-selective inhibition of cardiac Na(+) channel current (I(Na)) and I(Na)-dependent parameters has been shown to contribute to the safe and effective management of atrial fibrillation. The present study examined the basis for the atrial-selective actions of ranolazine. Whole cell I(Na) was recorded at 15°C in canine atrial and ventricular myocytes and in human embryonic kidney (HEK)-293 ce...

Journal: :JACC. Cardiovascular imaging 2009
Rajesh Venkataraman Luiz Belardinelli Brent Blackburn Jaekyeong Heo Ami E Iskandrian

OBJECTIVES This study examined the hypothesis that the improvement in myocardial blood flow (MBF) with ranolazine therapy could be detected by serial automated quantitative myocardial perfusion imaging (MPI) in patients with coronary artery disease (CAD) and myocardial ischemia. BACKGROUND Myocardial ischemia enhances late sodium current, which then causes cellular calcium overload leading to...

2013
Alessandro Santoro Vincenzo Schiano Lomoriello Ciro Santoro Riccardo Muscariello Maurizio Galderisi

In a 61-year-old woman with well controlled arterial hypertension, hypercholesterolemia, and smoke and suffering from recurrent angina pectoris despite angiographically normal epicardial coronary vessels and maximal therapy, the replacement of nitrates with novel antiangina drug ranolazine, after 6-month therapy, induced a complete relief of angina and a relevant rising of the transthoracic Dop...

2014
Peyman Mesbah Oskui Guy S Mayeda Steven Burstein Ali Gheissari William J French Joseph Thomas Robert A Kloner

We report the case of a 59-year-old woman who presented with symptoms of angina that was refractory to medical management. Although her cardiac catheterization revealed microvascular coronary artery disease, her symptoms were refractory to optimal medical management that included ranolazine. After undergoing transmyocardial revascularization, her myocardial ischemia completely resolved and her ...

2010
Jessica L. Mega Judith S. Hochman

Background—The pathobiological basis of ischemic heart disease and thus the manifestations and response to therapy can differ between women and men. In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women. Methods and Results—We conducted a prospectively planned analysis of the clinical, biomarker, angiogr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید